Zalevsky Jonathan 4

What Happened
Jonathan Zalevsky, Chief Research & Development Officer at Nektar Therapeutics (NKTR), sold 3,867 shares on 2026-01-20 in an open-market transaction. The weighted average sale price was $35.67, resulting in proceeds of approximately $137,936. This transaction is reported as a sale (code S).

Key Details

• Transaction date: 2026-01-20 (reported on Form 4 filed 2026-01-22). Filing appears timely (within required reporting window).
• Shares sold: 3,867; weighted average price: $35.67; total proceeds: ~$137,936.
• Price range (multiple trades): $35.17 to $36.23 (reported as weighted average; reporting person will provide detailed trade-by-trade prices/quantities upon request).
• Footnotes: Transaction executed under a Rule 10b5-1 trading plan adopted May 16, 2025.
• Shares owned after transaction: Not specified in this filing.

Context

• This was an open-market sale executed under a pre-established 10b5-1 plan; such plans typically schedule trades in advance and are not, by themselves, evidence of a change in the insider’s view of the company.
• Sales by executives can be routine (liquidity, diversification, tax planning) and do not necessarily signal material company developments.